{"result": {"id": "1d624d5d-dd5b-46b8-bbf1-fe5e414d6e3a", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-converting enzyme inhibitors, a class of RAS inhibitor drugs used for hypertension and heart conditions\")  \n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin II receptor blockers, a class of RAS inhibitor drugs used for hypertension and kidney protection\")  \n##\n(\"entity\"<|>ARNI<|>ORGANIZATION<|>Angiotensin receptor-neprilysin inhibitors, a combined RAS inhibitor therapy for cardiovascular conditions\")  \n##\n(\"entity\"<|>DAPAGLIFLOZIN<|>ORGANIZATION<|>A specific SGLT2 inhibitor drug used to treat diabetes and reduce kidney/cardiovascular risks\")  \n##\n(\"entity\"<|>EMPAGLIFLOZIN<|>ORGANIZATION<|>A specific SGLT2 inhibitor drug used to treat diabetes and heart failure\")  \n##\n(\"entity\"<|>FINERENONE<|>ORGANIZATION<|>A third-generation MRA drug used for diabetic kidney disease\")  \n##\n(\"entity\"<|>LVH<|>EVENT<|>Left ventricular hypertrophy, a cardiac complication of hypertension\")  \n##\n(\"entity\"<|>IMT<|>EVENT<|>Carotid intima-media thickness, a marker of arterial stiffness and cardiovascular risk\")  \n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both are classes of RAS inhibitors with similar therapeutic effects<|>8)  \n##\n(\"relationship\"<|>ARNI<|>ACEI<|>ARNI combines neprilysin inhibition with RAS blockade (ACEI/ARB mechanisms)<|>7)  \n##\n(\"relationship\"<|>DAPAGLIFLOZIN<|>EMPAGLIFLOZIN<|>Both are SGLT2 inhibitors with similar mechanisms of action<|>7)  \n##\n(\"relationship\"<|>FINERENONE<|>MRA<|>Finerenone is a third-generation MRA drug<|>9)  \n##\n(\"relationship\"<|>CCB<|>IMT<|>CCBs can reduce carotid IMT progression<|>6)  \n##\n(\"relationship\"<|>RAS INHIBITORS<|>LVH<|>RAS inhibitors are effective in reducing left ventricular hypertrophy<|>7)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558696, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 526, "prompt_tokens": 2933, "total_tokens": 3459, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2880}, "prompt_cache_hit_tokens": 2880, "prompt_cache_miss_tokens": 53}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 脏疾病进展速度[389] 。有证据表明 , 治疗 引起的 eGFR 变 化 可 预 测 心 血 管 事 件 和 ESRD 进 展[390] 。2020年的一项大规模荟萃分析显示[391]  ,心血 管风险随着颈动脉IMT进展的减少而降低。\n　　　不同药物改善或逆转靶器官损害的作用可能并不 完全相同 。CCB可显著改善动脉弹性 , 降低颈动脉 IMT,延缓冠状动脉或颈动脉粥样硬化及周围血管病 进展[245,392,393] 。RAS抑制剂(ACEI、ARB和 ARNI) 在改善 LVH 以及降低微量白蛋白尿和蛋白尿水平方 面有显著效果[394-396] 。SGLT2i(达格列净和恩格列净) 能够在 RAS抑制剂基础上进一步降低微量白蛋白尿 , 延缓肾脏疾病进展、降低心血管及肾脏事件发生风 险[397-399] 。第三代 MRA(非奈利酮) 在糖尿病肾病患 者中具有降低微量白蛋白尿的作用 ,并可降低心血管 及肾脏事件发生的风险[400] 。\n5.5   高血压治疗随访\n　5.5.1   随访目的   随诊是高血压管理的重要组成部 分 。随诊目的包括评估治疗反应 , 了解患者对药物的 依从性和耐受情况 ,分析血压是否稳定达标、其他危险 因素的控制状况以及检查靶器官损害的发展或变化 , 建立医患相互信任的良好关系。\n　5.5.2   随访内容   随访的主要内容是观察血压、用药 情况、不良反应 , 同时应关注血脂、血糖等其他危险因 素、靶器官损害和临床疾患 。测量诊室血压 , 了解血压 数值及达标状态 ,询问服药的依从性 ,根据血压的波动 以及药物的不良反应进行高血压治疗药物的调整 , 嘱 咐患者按时服药 ,指导患者改善生活方式、坚持长期治 疗 ,不随意停药。\n　　　强烈鼓励使用 HBPM ,最好是使用自动电子血压 计测量、记录和存储的长期、连续的 HBPM 数据 。根 据不同血压表型、随诊间 BPV 以及判断 24h血压控 制等情况的需要 , 随诊内容应考虑包括 ABPM。靶器 官损害评估应成为高血压患者随访的重要内容 ,可以 帮助判断治疗效果[108] 。\n　5.5.3   随访间隔   在开始治疗后的前 3月内 ,建议每 月随访 1次[139] 。根据患者的心血管总体风险及血压\n\n\n水平可调整随访间隔 。高血压 1级 ,危险分层属低危、 中危或仅服 1种药物治疗者 ,可每 1~3月随访 1次 ;  复杂病例、高危\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ESRD<|>EVENT<|>End-stage renal disease, a severe kidney condition that can progress from chronic kidney disease\")  \n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium channel blockers, a class of medications used to treat hypertension and heart conditions\")  \n##\n(\"entity\"<|>RAS INHIBITORS<|>ORGANIZATION<|>Renin-angiotensin system inhibitors, including ACEI, ARB, and ARNI, used to manage hypertension and kidney disease\")  \n##\n(\"entity\"<|>SGLT2I<|>ORGANIZATION<|>Sodium-glucose cotransporter-2 inhibitors, such as dapagliflozin and empagliflozin, used to treat diabetes and reduce cardiovascular risks\")  \n##\n(\"entity\"<|>MRA<|>ORGANIZATION<|>Mineralocorticoid receptor antagonists, including finerenone, used to treat diabetic kidney disease\")  \n##\n(\"entity\"<|>HBPM<|>EVENT<|>Home blood pressure monitoring, a method for tracking blood pressure outside clinical settings\")  \n##\n(\"entity\"<|>ABPM<|>EVENT<|>Ambulatory blood pressure monitoring, a technique for measuring blood pressure over 24 hours\")  \n##\n(\"relationship\"<|>RAS INHIBITORS<|>SGLT2I<|>SGLT2i can further reduce microalbuminuria when used alongside RAS inhibitors<|>7)  \n##\n(\"relationship\"<|>SGLT2I<|>MRA<|>Both SGLT2i and MRA are used to reduce cardiovascular and kidney risks in diabetic patients<|>6)  \n##\n(\"relationship\"<|>CCB<|>RAS INHIBITORS<|>CCB and RAS inhibitors are both classes of drugs used to manage hypertension and target organ damage<|>5)  \n##\n(\"relationship\"<|>HBPM<|>ABPM<|>Both HBPM and ABPM are methods for monitoring blood pressure, with ABPM providing 24-hour data<|>4)  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_63d6026c125efee09172243c769f4b3c871cdc195c7ba66d3329a91ff9409992_v2"}